Standout Papers

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inh... 2021 2026 2022 2024214
  1. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (2021)
    Hope S. Rugo, Florence Lerebours et al. The Lancet Oncology

Immediate Impact

2 by Nobel laureates 28 from Science/Nature 61 standout
Sub-graph 1 of 23

Citing Papers

Hallmarks of aging: An expanding universe
2023 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
5 intermediate papers

Works of Pamela Drullinsky being referenced

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
2021 Standout
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
2018
and 2 more

Author Peers

Author Last Decade Papers Cites
Pamela Drullinsky 598 466 175 515 57 1.3k
Daniel Wai 502 604 247 930 41 1.7k
Giuliana Cavalloni 694 367 190 497 49 1.6k
Cristina Santos 1108 272 359 465 49 1.6k
Debra Saxe 297 224 167 566 45 1.4k
Preston D. Steen 567 321 122 255 47 1.0k
Binaifer Balsara 395 368 202 918 37 1.6k
David D. Chism 541 480 64 675 29 1.7k
Davide Nicoli 225 436 60 370 70 1.4k
Susan J. Hsiao 439 199 213 604 47 1.3k
Simone Hettmer 264 500 208 704 61 1.3k

All Works

Loading papers...

Rankless by CCL
2026